<DOC>
	<DOCNO>NCT00705185</DOCNO>
	<brief_summary>The purpose study develop blood test major depression measure effect ziprasidone monotherapy marker . Specific Aim : Using multiplex biomarker assay measure level 16 biomarkers patient MDD enrol ancillary study ( adjunct study NCT00555997 ) compare result healthy control '' ( define research subject meet criterion lifetime Axis-I disorder ( DSM-IV ) ) exist dataset PHB .</brief_summary>
	<brief_title>Exploring Potential Blood Test Diagnose Major Depressive Disorder</brief_title>
	<detailed_description>This propose study ancillary study clinical trial NCT00555997 ( www.clinicaltrials.gov ) entitle : `` A 12-Week , Randomized , Double-Blind , Placebo-Controlled , Parallel-Sequential Trial Ziprasidone Monotherapy Major Depressive Disorder '' ( MDD ) . '' Precision Human Biolaboratory ( `` PHB '' ) attempt develop proprietary blood test intend potentially serve biological marker ( `` bio-marker '' ) MDD . Specifically , PHB 's research team employ unique approach towards develop diagnostic test MDD : measure multiple blood-based biological marker obtain patient MDD analyze use several interrelated algorithm order derive single biological measure ( `` bio-marker '' ) high predictive value MDD . PHBs ' test panel blood-based biological marker consist number cytokine , stress relate hormone , bind protein link MDD . This innovative test panel expect provide general practice physician tool accurately identify classify patient MDD , turn , could potentially , allow effective monitoring pharmacotherapy ( antidepressant drug therapy ) . Thus , development highly reliable biomarker MDD could improve standard care depression . For ancillary study , 120 antidepressant-free outpatient MDD deem eligible participate trial NCT00555997 recruit participate center . Participating subject undergo blood draw baseline visit NCT00555997 . Values obtain compare `` healthy control '' ( define research subject meet criterion lifetime Axis-I disorder ( DSM-IV ) ) exist dataset PHB .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Age 1865 . Written informed consent . MDD , current accord fourth version Diagnostic Statistical Manual Mental Disorders ( DSMIV ) diagnose Mini International Neuropsychiatric Interview ( MINI ; Sheehan et al , 1998 ) . Quick Inventory Depressive Symptomatology SelfRated ( QIDSSR Trivedi et al , 2004 ) score least 10 screen baseline visit . Pregnant woman . Women child bear potential use medically accept mean contraception ( include oral contraceptive implant , condom , diaphragm , spermicide , intrauterine device , tubal ligation , partner vasectomy ) . Treatment antidepressant 2 week prior screen visit . If interested discontinue current medication , potential participant must discuss possibility prescribe physician . Study doctor implement form treatment washout . Patients longer meet DSMIV criterion MDD baseline visit , patient demonstrate 25 % great reduction QIDSSR score , screen baseline . Serious suicide homicide risk , assess evaluate clinician score 4 third item HAMD . Unstable medical illness include cardiovascular , hepatic , renal , respiratory , endocrine , neurological , hematological disease . Patients meet criterion alcohol substance dependence , active within last month . Any bipolar disorder ( current past ) . Any psychotic disorder ( current past ) . Psychotic feature current episode history psychotic feature . History seizure disorder . Clinical laboratory evidence untreated hypothyroidism . Patients require excluded medication ( see table 1 detail ) . Prior course ziprasidone , intolerance ziprasidone dose . Any investigational psychotropic drug within last 3 month . Patients significant cardiac conduction problem screen electrocardiogram atrial fibrillation , atrial flutter , atrioventricular block , prolong abnormal QTc interval ( i.e . QTc &gt; 450msec ) , prolong QRS interval . Patients suffer myocardial infarction within past 12 month , uncompensated heart failure , history QTc prolongation . Patients abnormal serum potassium magnesium level upon screen . Patients currently take drug prolong QTc include dofetilide , sotalol , quinidine , class Ia antiarrhythmic , class III antiarrhythmic , mesoridazine , thioridazine , chlorpromazine , droperidol , pimozide , sparfloxacin , gatifloxacin , moxifloxacin , halofantrine , mefloquine , pentamidine , arsenic trioxide , levomethadyl acetate , dolasetron methylate , probucol tacrolimus . Patients fail experience significant clinical improvement follow 3 antidepressant trial adequate duration ( least 6 week ) dose ( minimal effective dos define : fluoxetine , paroxetine , citalopram 20mg ; sertraline , fluvoxamine 50mg , escitalopram 10mg , paroxetine CR 25mg , venlafaxine 75mg , duloxetine 60mg , bupropion 150mg , 15mg mirtazapine , trazodone nefazodone 300mg ) . The presence Addison 's Cushing 's disease . The presence rheumatoid arthritis , systemic lupus erythematosus . The regular use nonsteroidal antiinflammatory medication oral steroid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Blood Test</keyword>
</DOC>